Related Experiment Video
Updated: May 9, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
[Cerebral embolism and atrial fibrillation]
1Department of Neurology, Toranomon Hospital, Tokyo, Japan.
Insights
Warfarin anticoagulation for atrial fibrillation (Af) in Japan is often insufficient, and combining it with antiplatelets is harmful. New oral anticoagulants (NOACs) offer convenience and safety but require proper usage guidelines.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Context:
- Atrial fibrillation (Af) is a primary cause of cerebral embolisms.
- Warfarin anticoagulation is prevalent in Japan but often sub-therapeutic.
- Concomitant use of warfarin and antiplatelets lacks evidence and poses risks.
Purpose:
- To review the challenges of warfarin therapy in Af patients.
- To evaluate the role and risks of antiplatelets in Af.
- To discuss the advantages and uncertainties surrounding new oral anticoagulants (NOACs).
Summary:
- Warfarin therapy for Af in Japan frequently shows insufficient anticoagulation intensity.
- Evidence does not support the efficacy of antiplatelets for embolism prevention in Af.
- Concomitant warfarin and antiplatelet use is potentially harmful, particularly concerning intracranial hemorrhage.
- New oral anticoagulants (NOACs) present a more convenient and safer alternative, enabling broader application in lower-risk patients.
- Optimal strategies for utilizing the different available NOACs remain to be clarified.
Impact:
- Highlights the need for optimized anticoagulation strategies in Af.
- Warns against the unproven and risky combination of warfarin and antiplatelets.
- Suggests NOACs can expand anticoagulation therapy to broader patient populations.
- Identifies a critical knowledge gap in the clinical application of NOACs.
Abstract:
Atrial fibrillation (Af) is the most important cause of cerebral embolisms, and the effects of anticoagulation therapy have been firmly established. The use of warfarization in patients with Af is greater than expected in Japan, but the intensity of anticoagulation has often been insufficient. Antiplatelets, especially aspirin, are prescribed because of a possible preventive effect on embolisms. However, there is no evidence of such an efficacy, and the concomitant use of warfarin and antiplatelets is not good and potentially harmful, at least to the brain. The prescription of warfarin is burdensome for many outpatient clinics, probably because the anticoagulation effects of warfarin fluctuate because of the influence of many factors. Several factors, such as renal function, liver function, and some drug interactions, should be considered when we prescribe new oral anticoagulants (NOACs). NOACs are convenient compared to warfarin, and the lower incidence of intracranial hemorrhage allows anticoagulation treatment to be expanded from patients with Af to patients with lower risks of embolism, such as patients with 1 point on the CHADS(2) score. However, it is still unclear how to use the 3 different NOACs properly.
More Related Videos
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Ischemic Stroke l: Introduction
Cerebral Edema ll: Pathophysiology
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

